0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

No Association Between SRGAP3/MEGAP Haploinsufficiency and Mental Retardation FREE

Fadi F. Hamdan, PhD; Julie Gauthier, PhD; Stéphanie Pellerin, RN; Sylvia Dobrzeniecka, MSc; Claude Marineau, MSc, MBA; Éric Fombonne, MD; Laurent Mottron, MD, PhD; Ronald G. Lafrenière, PhD; Pierre Drapeau, PhD; Jean Claude Lacaille, PhD; Guy A. Rouleau, MD, PhD; Jacques L. Michaud, MD
Arch Neurol. 2009;66(5):675-677. doi:10.1001/archneurol.2009.65.
Text Size: A A A
Published online

Mental retardation (MR) affects 2% to 3% of children and is defined by the presence of significant limitations in cognitive and adaptive behavior.1 A classic neuropathological feature of patients with MR is altered dendritic spine morphology and/or density. These structural abnormalities reflect impaired cytoskeleton remodeling and are associated with synaptic dysfunction.2 Members of the Rho family of guanosine triphosphateses (Rho GTPases) regulate cytoskeletal remodeling in the context of dendritic structures and synaptic plasticity. Mutations in several genes of the Rho-GTPase signaling pathway have been reported in MR.3 One example of such genes is SRGAP3/MEGAP, which encodes a Rho-GTPase activator (RhoGAP) that regulates actin remodeling.4,5 The SRGAP3 gene was disrupted by a de novo balanced translocation in a patient with facial dysmorphism, hypotonia, and severe MR, features characteristic of 3p− microdeletion syndrome.4 The breakpoint was located between exons 3 and 4 of SRGAP3, and the translocation did not seem to be associated with copy number changes. SRGAP3 was also found to be among the genes deleted in some patients with 3p− microdeletion syndrome.4 Together, these observations suggest that SRGAP3 haploinsufficiency causes MR.

As part of the Synapse-to-Disease project aimed at performing large-scale mutation analysis of genes affecting the synapse in neurodevelopmental diseases, we sequenced SRGAP3 in patients with idiopathic MR (n = 95) or autism spectrum disorders (ASD; n = 142). Our findings suggest that heterozygous disruption of SRGAP3 is not associated with MR.

Cohorts of 95 sporadic cases of MR (without growth abnormalities or dysmorphic features), 142 patients with ASD, and 285 healthy ethnically matched individuals were recruited. Most individuals with MR or ASD and control individuals were French Canadian. After approval by the institutional ethics committees, blood samples were collected from all individuals and from their parents for genomic DNA extraction (Puregene DNA kit; Qiagen, Mississauga, Ontario, Canada). Paternity and maternity of all families were confirmed using 6 microsatellite markers. Twenty-two coding exons and their intronic flanking regions from SRGAP3 (chr3:8997278-9266311; RefSeq NM_014850) were amplified by polymerase chain reaction from genomic DNA and directly sequenced. Mutations were confirmed by reamplification and resequencing of the proband and the parents in both directions.

We identified the following 5 heterozygous missense mutations in SRGAP3: p.E394V (c.1181A>T; ASD:1/142), p.F511L (c.1531T>C; ASD:2/142), p.I628V (c.1882A>G; MR:1/95; ASD:1/142; dbSNP:rs2271207), p.V799I (c.2395G>A; MR:1/95), and p.G942C (c.2824G>T; ASD:1/142) (Figure). These mutations are predicted not to affect protein function6 and are unlikely to be pathogenic, as they are transmitted from healthy parents. We also identified one heterozygous nonsense mutation (c.1162C>T; p.Q388X) in a different patient with MR. This mutation lies in exon 8, before the alternatively spliced exon 12, and is predicted to truncate SRGAP3 upstream of its RhoGAP domain4; thus, it is expected to abolish SRGAP3 function (Figure). The proband with p.Q388X is an 18-year-old French Canadian woman with mild nonsyndromic MR. The heterozygous p.Q388X was also found in the DNA of the proband's mother, maternal uncle, and maternal grandfather, who are all healthy and display no cognitive deficits. This mutation was absent from the proband's healthy father and brother, from her sister who also shows mild nonsyndromic MR, and from 285 ethnically matched controls.

Place holder to copy figure label and caption
Figure.

Heterozygous SRGAP3 mutations in cohorts with mental retardation (MR) and autism spectrum disorders. A, Amino acid positions are based on the longest isoform of SRGAP3 (isoform A, 1099 amino acids; GenPept NP_055665). The various predicted functional domains of SRGAP3 are shown according to Universal Protein Resource database (Uniprot) Fes/CIP4 homology domain position, 22-87; RhoGAP position, 482-670; and Src homology 3 domain, 720-779. B and C, The family shows a p.Q388X SRGAP3 mutation. B, The proband is indicated by an arrow. Solid circles represent the sisters with MR. C, Representative chromatograms with or without the p.Q388X mutation are shown with corresponding amino acids.

Graphic Jump Location

Here we describe a heterozygous SRGAP3-truncating mutation in 3 healthy individuals and 1 patient with MR, all from the same family. This finding and the fact that p.Q388X was found only in 1 of 2 sisters sharing a similar MR phenotype argue against the notion that heterozygous disruption of SRGAP3 causes MR. The previously described association between SRGAP3 and MR mainly relied on the observation of a balanced translocation disrupting this gene in a patient with MR.4 Balanced translocations are complex rearrangements that can cause disease through gain- and/or loss-of-function mechanisms. It remains unknown whether this translocation is coincidental in this patient, whether it causes MR by disrupting the expression of another gene, or whether it induces a gain-of-function effect that could involve SRGAP3.

ARTICLE INFORMATION

Correspondence: Dr Michaud, Research Center, Centre Hospitalier Iniversitaire Sainte-Justine, 3175 Côte Sainte-Catherine, Montreal, Quebec, Canada H3T 1C5 (jacques.michaud@recherche-ste-justine.qc.ca).

Author Contributions:Study concept and design: Hamdan, Gauthier, Marineau, Lafrenière, Drapeau, Lacaille, Rouleau, and Michaud. Acquisition of data: Pellerin, Dobrzeniecka, Fombonne, and Mottron. Analysis and interpretation of data: Hamdan and Dobrzeniecka. Drafting of the manuscript: Hamdan and Michaud. Critical revision of the manuscript for important intellectual content: Gauthier, Pellerin, Dobrzeniecka, Marineau, Fombonne, Mottron, Lafrenière, Drapeau, Lacaille, and Rouleau. Obtained funding: Drapeau, Lacaille, Rouleau, and Michaud. Administrative, technical, and material support: Pellerin, Dobrzeniecka, Marineau, Fombonne, and Mottron. Study supervision: Hamdan, Gauthier, Lafrenière, Rouleau, and Michaud.

Financial Disclosure: None reported.

Funding/Support: This study was supported by the Canadian Institute of Health Research (CIHR) (Drs Rouleau, Lacaille, and Michaud); Fonds de la Recherche en Santé (FRSQ) (Dr Michaud); Genome Canada; Genome Quebec; and Université de Montréal for the Synapse-to-Disease (S2D) project (Drs Drapeau and Rouleau).

Additional Contributions: Synapse-to-Disease team, including the bioinformatic (Yan Yang, Dan Spiegelman, Mélanie Côté, and Ousmane Diallo) and genetic screening and polymerase chain reaction divisions (Sandra Laurent, Anne Noreau, Frédéric Kuku, Joannie Duguay, Laurie Destroismaisons, Karine Lachapelle, Philippe Jolivet, Pascale Thibodeau, and Annie Raymond); DNA extraction and paternity testing, Annie Levert and Judith St-Onge; DNA sequencing and analyses at the McGill University and Génome Québec Innovation Centre, Pierre Lepage, Sébastien Brunet, Hao Fan Yam, Louis Létourneau, and Louis Dumond Joseph.

Chelly  JKhelfaoui  MFrancis  FChérif  BBienvenu  T Genetics and pathophysiology of mental retardation. Eur J Hum Genet 2006;14 (6) 701- 713
PubMed Link to Article
Kaufmann  WEMoser  HW Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex 2000;10 (10) 981- 991
PubMed Link to Article
Newey  SEVelamoor  VGovek  EEVan Aelst  L Rho GTPases, dendritic structure, and mental retardation. J Neurobiol 2005;64 (1) 58- 74
PubMed Link to Article
Endris  VWogatzky  BLeimer  U  et al.  The novel Rho-GTPase activating gene MEGAP/ srGAP3 has a putative role in severe mental retardation. Proc Natl Acad Sci U S A 2002;99 (18) 11754- 11759
PubMed Link to Article
Yang  YMarcello  MEndris  V  et al.  MEGAP impedes cell migration via regulating actin and microtubule dynamics and focal complex formation. Exp Cell Res 2006;312 (12) 2379- 2393
PubMed Link to Article
Ng  PCHenikoff  S SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31 (13) 3812- 3814
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure.

Heterozygous SRGAP3 mutations in cohorts with mental retardation (MR) and autism spectrum disorders. A, Amino acid positions are based on the longest isoform of SRGAP3 (isoform A, 1099 amino acids; GenPept NP_055665). The various predicted functional domains of SRGAP3 are shown according to Universal Protein Resource database (Uniprot) Fes/CIP4 homology domain position, 22-87; RhoGAP position, 482-670; and Src homology 3 domain, 720-779. B and C, The family shows a p.Q388X SRGAP3 mutation. B, The proband is indicated by an arrow. Solid circles represent the sisters with MR. C, Representative chromatograms with or without the p.Q388X mutation are shown with corresponding amino acids.

Graphic Jump Location

Tables

References

Chelly  JKhelfaoui  MFrancis  FChérif  BBienvenu  T Genetics and pathophysiology of mental retardation. Eur J Hum Genet 2006;14 (6) 701- 713
PubMed Link to Article
Kaufmann  WEMoser  HW Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex 2000;10 (10) 981- 991
PubMed Link to Article
Newey  SEVelamoor  VGovek  EEVan Aelst  L Rho GTPases, dendritic structure, and mental retardation. J Neurobiol 2005;64 (1) 58- 74
PubMed Link to Article
Endris  VWogatzky  BLeimer  U  et al.  The novel Rho-GTPase activating gene MEGAP/ srGAP3 has a putative role in severe mental retardation. Proc Natl Acad Sci U S A 2002;99 (18) 11754- 11759
PubMed Link to Article
Yang  YMarcello  MEndris  V  et al.  MEGAP impedes cell migration via regulating actin and microtubule dynamics and focal complex formation. Exp Cell Res 2006;312 (12) 2379- 2393
PubMed Link to Article
Ng  PCHenikoff  S SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31 (13) 3812- 3814
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

792 Views
10 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs